华海药业 - 业绩回顾：2025 年上半年基本符合预期；目标价上调至 15 元人民币，反映积极管线进展

26 August 2025 | 3:37PM CST Zhejiang Huahai Pharmaceutical (600521.SS): Earnings review: 1H25 results mostly in line; TP up to Rmb15 to reflect positive pipeline Huahai released its 1H25 results on Aug 25, 2025. Both its revenue (Rmb4,516mn, -12% yoy) and net profits (Rmb409mn, -45% yoy) were mostly in-line with GSe (Rmb4,748mn/398mn, respectively). We are positive on the company's pipeline progress (which all belong to the company's subsidiary, Huaota Biotech; see the company's latest pipeline in Exhibit 1 ...